Prognostic significance of baseline neutrophil-lymphocyte ratio in patients with non-small-cell lung cancer: a pooled analysis of open phase III clinical trial data

被引：9
作者：
Huang, Liling [1 ]
Jiang, Shiyu [2 ]
Shi, Yuankai [1 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Dept Med Oncol, Beijing Key Lab Clin Study Anticanc Mol Targeted, Natl Canc Ctr,Natl Clin Res Ctr Canc,Canc Hosp, Beijing 100021, Peoples R China
[2] Fudan Univ, Fudan Univ Shanghai Canc Ctr, Shanghai Med Coll, Dept Med Oncol, Shanghai 200032, Peoples R China
来源：
FUTURE ONCOLOGY | 2022年 / 18卷 / 14期
关键词：
neutrophil-lymphocyte ratio; NLR; non-small-cell lung cancer; prognosis; survival; IMMUNE CHECKPOINT INHIBITORS; FEBRILE NEUTROPENIA; RISK MODEL; INFLAMMATION; LYMPHOPENIA; THERAPY; CHEMOTHERAPY; TRANSFUSION; REFLECTS;
D O I：
10.2217/fon-2021-1304
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Aim: This study aimed to assess survival and hematological prognostic indicators of patients with non-small-cell lung cancer (NSCLC). Material & methods: Through the Project Data Sphere portal, two phase III clinical trial datasets were downloaded to analyze survival outcomes and related risk factors. Results: The median progression-free survival and overall survival of 756 patients with stage III-IV NSCLC were 6.2 and 14.2 months, respectively. In multivariate Cox analysis, high baseline neutrophil-lymphocyte ratio (NLR; >= 3.8) was associated with worse progression-free survival (hazard ratio: 1.37; p = 0.0004) and overall survival (hazard ratio: 1.65; p < 0.0001). In addition, it exerted an unfavorable impact on survival across multiple subgroups. Conclusions: NLR, a powerful inflammatory and immunologic indicator, is an independent prognostic indicator in patients with advanced NSCLC.
引用
收藏
页码：1679 / 1689
页数：11
相关论文
共 43 条
[1]   Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis [J].
Benedict Sacdalan, Danielle ;
Anne Lucero, Josephine ;
Lee Sacdalan, Dennis .
ONCOTARGETS AND THERAPY, 2018, 11 :955-965
[2]   A risk model for thrombocytopenia requiring platelet transfusion after cytotoxic chemotherapy [J].
Blay, JY ;
La Cesne, A ;
Mermet, C ;
Maugard, C ;
Ravaud, A ;
Chevreau, C ;
Sebban, C ;
Guastalla, JP ;
Biron, P ;
Ray-Coquard, I .
BLOOD, 1998, 92 (02) :405-410
[3]   CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer [J].
Borg, C ;
Ray-Coquard, I ;
Philip, I ;
Clapisson, G ;
Bendriss-Verma, N ;
Menetrier-Caux, C ;
Sebban, C ;
Biron, P ;
Blay, JY .
CANCER, 2004, 101 (11) :2675-2680
[4]   Neutrophils, from Marrow to Microbes [J].
Borregaard, Niels .
IMMUNITY, 2010, 33 (05) :657-670
[5]   Radiation Therapy Quality Assurance (RTQA) of Concurrent Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer in the PROCLAIM Phase 3 Trial [J].
Brade, Anthony M. ;
Wenz, Frederik ;
Koppe, Friederike ;
Lievens, Yolande ;
San Antonio, Belen ;
Iscoe, Neill A. ;
Hossain, Anwar ;
Chouaki, Nadia ;
Senan, Suresh .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 101 (04) :927-934
[6]   Significant Downregulation of Platelet Gene Expression in Metastatic Lung Cancer [J].
Calverley, David C. ;
Phang, Tzu L. ;
Choudhury, Qamrul G. ;
Gao, Bifeng ;
Oton, Ana B. ;
Weyant, Michael J. ;
Geraci, Mark W. .
CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2010, 3 (05) :227-232
[7]   Baseline anemia and anemia grade are independent prognostic factors for stage IV non-small cell lung cancer [J].
Chen, Cheng ;
Song, Zhengbo ;
Wang, Wenxian ;
Zhou, Juying .
MOLECULAR AND CLINICAL ONCOLOGY, 2021, 14 (03)
[8]   Neutrophils in cancer: neutral no more [J].
Coffelt, Seth B. ;
Wellenstein, Max D. ;
de Visser, Karin E. .
NATURE REVIEWS CANCER, 2016, 16 (07) :431-446
[9]   Tumour burden and efficacy of immune-checkpoint inhibitors [J].
Dall'Olio, Filippo G. ;
Marabelle, Aurelien ;
Caramella, Caroline ;
Garcia, Camilo ;
Aldea, Mihaela ;
Chaput, Nathalie ;
Robert, Caroline ;
Besse, Benjamin .
NATURE REVIEWS CLINICAL ONCOLOGY, 2022, 19 (02) :75-90
[10]   Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab [J].
Diem, Stefan ;
Schmid, Sabine ;
Krapf, Mirjam ;
Flatz, Lukas ;
Born, Diana ;
Jochum, Wolfram ;
Templeton, Arnoud J. ;
Fruh, Martin .
LUNG CANCER, 2017, 111 :176-181
12345